Table 2.
Patient characteristics
| Study | Age | Sex | Baseline severity of COPD | Duration of inhaled steroid use prior to entry into trial | Mean baseline FEV1 | Mean baseline number of exacerbations in year preceding trial |
|---|---|---|---|---|---|---|
| WISP14 | > 40 | Male & female | Post-bronchodilator FEV1 < 80% predicted | Minimum 6 months, mean 8 years | Withdrawn group: 1.40 L Steroid group: 1.31 L (post-bronchodilator) |
Withdrawn group: 1.86 Steroid group: 1.93 |
| O'Brien et al17 | 40-79 | Male | Details not provided | Details not provided | 1.61 L | Details not provided |
| COPE15 | 40-75 | Male & female | Pre-bronchodilator FEV1 25-80% predicted | 83% of patients had used for at least 6 months | Withdrawn group: 1.69 L Steroid group: 1.78 L (post-bronchodilator) |
All patients: 1.3 |
| COSMIC16 | 40-75 | Male & female | Pre-bronchodilator FEV1 30-70% predicted | Details not provided | Withdrawn group: 49.0 Steroid group: 48.1 (pre-bronchodilator % predicted) |
Details not provided, all patients had 2 or more requiring treatment |